Several potential reasons exist for the contrast to previous reports, including (1) differences between normal cells and different cancer cells in antiviral signaling, (2) constitutive activation of NF-κB pathway in a majority of PDACs, and (3) different timing and level of expression for VSV-encoded p53 in the cell lines used in this study. The gene discussed is TP53; the disease is cancer.